ATLANTA, Feb. 17, 2026 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Mereo BioPharma Group plc (“Mereo” or the “Company”) (NASDAQ: MREO). The lawsuit alleges that Defendants issued false and misleading statements and/or failed to disclose material adverse facts, including allegations that Defendants concealed and misrepresented facts regarding setrusumab’s ability to achieve statistical significance for the primary endpoints in both the ORBIT and COSMIC studies. If you purcha ...

Core Viewpoint - BioLife Solutions, Inc. is set to release its fourth quarter and full year 2025 financial results on February 26, 2026, along with a business update [1] Company Overview - BioLife Solutions is a leading developer and supplier of bioproduction products and services specifically for the cell and gene therapy (CGT) market [1] - The company provides solutions that maintain the health and function of biologic materials during various stages including collection, development, storage, and distribution [1] Financial Reporting - The financial results will be discussed in a conference call and live webcast scheduled for 4:30 PM ET (1:30 PM PT) on the release date [1] - Access to the webcast will be available through the Investor Relations page of the BioLife Solutions website [1] Contact Information - The Chief Financial Officer, Troy Wichterman, can be contacted for media and investor relations inquiries [1]

Core Insights - CERo Therapeutics Holdings, Inc. has appointed Eric Francois to its Board of Directors, which is expected to enhance the company's strategic direction and operational capabilities [1][2]. Company Overview - CERo is an innovative cellular immunotherapy company focused on developing next-generation engineered T cell therapeutics for cancer treatment [3]. - The company’s proprietary approach integrates both innate and adaptive immunity to create a more effective therapeutic construct for tumor targeting [3]. Leadership and Expertise - Eric Francois brings over 25 years of experience in the life sciences sector, including significant roles in financial advisory and capital raising, having raised over $300 million during his tenure as CFO of SCYNEXIS [2]. - His expertise in mergers and acquisitions, along with business development, is anticipated to be a valuable asset for CERo at this stage of its growth [2]. Product Development - CERo has initiated clinical trials for its lead product candidate, CER-1236, targeting hematologic malignancies, showcasing its commitment to advancing innovative cancer therapies [3]. - The company’s unique Chimeric Engulfment Receptor T cells (CER-T) are designed to utilize phagocytic activity to destroy cancer cells, potentially offering advantages over existing CAR-T therapies [3].

February 2026 Bitopertin Regulatory Update Disclaimer and FLS This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, express or implied statements regarding Disc's expectations with respect to its preclinical studies, clinical trials and research and development programs, in particular with respect to bitopertin, DISC-0974 and DISC-3405, and any developments or results in connection therewith; project ...

SUMMIT NDA for bezuclastinib in patients with NonAdvSM submitted in December 2025; APEX NDA submission for bezuclastinib in patients with AdvSM on track for 1H 2026PEAK NDA initiated for bezuclastinib in patients with 2L GIST under Real-Time Oncology Review (RTOR) and Breakthrough Therapy Designation (BTD); completion of NDA on track for April 2026Six abstracts from SUMMIT trial of bezuclastinib in patients with NonAdvSM accepted for presentation at 2026 AAAAI annual meetingStrong financial position with $9 ...

Company Overview - Chemomab Therapeutics Ltd. is a clinical stage biotechnology company focused on developing innovative therapeutics for fibro-inflammatory diseases with high unmet need [3] - The company has developed nebokitug, a first-in-class dual activity monoclonal antibody that neutralizes the soluble protein CCL24, which plays a role in promoting fibrosis and inflammation [3] - Nebokitug has shown disease-modifying potential and a favorable safety profile in clinical and preclinical studies, with positive results reported from five clinical trials [3] Clinical Development - Chemomab has aligned with the FDA on the design of a Phase 3 registration trial for nebokitug in patients with primary sclerosing cholangitis (PSC) based on positive data from its Phase 2 SPRING trial [3] - Nebokitug has received Orphan Drug designations from the FDA and EMA for the treatment of PSC, as well as Fast Track designation from the FDA [3] - The nebokitug program for systemic sclerosis has also received Orphan Drug designations and has an open U.S. IND [3] Upcoming Events - Chemomab's CEO Dr. Adi Mor and senior management will present at the virtual Oppenheimer 36 Annual Healthcare Life Sciences Conference on February 26, 2026 [1] - The corporate presentation will be webcast live and available for 90 days on the Chemomab investor relations website [1]

Core Insights - BostonGene has announced a strategic collaboration with Daiichi Sankyo to enhance antibody drug conjugate (ADC) development through AI-driven translational intelligence [1] Company Overview - BostonGene is recognized for developing a leading AI foundation model focused on tumor and immune biology [1] - Daiichi Sankyo is a prominent player in the pharmaceutical industry, specifically in the development of antibody drug conjugates [1] Collaboration Details - The collaboration aims to integrate advanced AI capabilities into Daiichi Sankyo's ADC development program [1] - The focus is on moving beyond traditional exploratory biomarker analysis to provide decision-ready insights for patient selection strategies [1]

Core Insights - Kane Biotech Inc. has achieved significant regulatory milestones that enhance its wound care platform and commitment to high-quality medical device development [1] Regulatory Approvals - The company has received FDA 510(k) clearance for its revyve Antimicrobial Skin and Wound Cleanser, which is designed for the cleansing and moistening of various acute and chronic dermal lesions, including pressure ulcers and diabetic foot ulcers [2] - This clearance validates Kane's expanded revyve product line, which targets wound bacteria and biofilms, key factors in delayed healing and antibiotic resistance [2] Certification Expansion - Kane has expanded its ISO 13485:2016 certification under the Medical Device Single Audit Program (MDSAP) to include distribution and wound cleansers, building on existing certifications for nonsterile antimicrobial wound dressings [3] - This expansion aligns with the FDA's new Quality Management System Regulation (QMSR) effective February 2026, harmonizing U.S. requirements with ISO 13485 [3] Commitment to Quality - The expanded certification supports Kane's ability to pursue regulatory approvals across multiple jurisdictions and demonstrates its investment in quality systems and operational readiness [4] - The Chief Quality Officer emphasized that compliance with ISO 13485 and MDSAP enhances trust among healthcare providers and patients, ensuring alignment with evolving regulatory expectations [5]

Core Insights - NeoGenomics reported a 10% increase in full-year revenue to $727 million, with clinical revenue growing 15% [1] - The company successfully resolved RaDaR ST patent litigation, enhancing its product offerings [1] Financial Performance - Fourth quarter consolidated revenue rose 11% to $190 million, while full-year consolidated revenue increased 10% to $727 million [1] - The net loss for the fourth quarter decreased by 36% to $10 million, but the full-year net loss increased by 37% to $108 million [1] - Adjusted EBITDA for the fourth quarter was positive at $13 million, a 13% increase, and for the full year, it rose 9% to $43 million [1] Growth Drivers - The company experienced a 23% growth in Next-Generation Sequencing (NGS) in Q4 and 22% for the full year, outpacing market growth [1] - The upcoming clinical launch of the RaDaR ST MRD assay is expected to tap into the $20+ billion molecular residual disease monitoring market [1] Operational Metrics - Average revenue per clinical test increased by 5% to $488, with a 7% growth excluding Pathline tests [1] - Consolidated gross profit for Q4 was $83 million, an 8% increase, leading to a gross profit margin of 43.8% [1] Future Guidance - For FY 2026, the company projects consolidated revenue between $793 million and $801 million, representing a 9% to 10% year-over-year increase [1] - The anticipated net loss for 2026 is expected to range from $63 million to $50 million, a significant improvement from 2025 [1]

Core Viewpoint - Pasithea Therapeutics Corp. is advancing its lead drug candidate, PAS-004, a next-generation macrocyclic oral MEK inhibitor, aimed at treating NF1-associated plexiform neurofibromas and is actively participating in the Oppenheimer 36th Annual Healthcare Life Sciences Conference [1][2]. Company Overview - Pasithea Therapeutics is a clinical-stage biotechnology company focused on the research and development of PAS-004, which targets RASopathies, MAPK pathway-driven tumors, and other diseases [4]. - The company is currently conducting a Phase 1 clinical trial for PAS-004 in advanced cancer patients (NCT06299839) and a Phase 1/1b clinical trial for adult patients with NF1-associated plexiform neurofibromas (NCT06961565) [4]. Event Details - The presentation by CEO Tiago Reis Marques is scheduled for February 26, 2026, from 4:00 to 4:30 PM ET, and will be available for viewing via a live webcast [2][3]. - Management will also be available for one-on-one meetings with qualified investors registered for the conference [2].